Compare ALT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALT | RLMD |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.4M | 348.8M |
| IPO Year | 2005 | 2012 |
| Metric | ALT | RLMD |
|---|---|---|
| Price | $1.45 | $2.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $16.33 | $10.75 |
| AVG Volume (30 Days) | ★ 3.8M | 1.7M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.37 | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 105.00 | ★ 154.83 |
| 52 Week Low | $1.50 | $2.98 |
| 52 Week High | $6.44 | $8.00 |
| Indicator | ALT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 36.14 |
| Support Level | N/A | N/A |
| Resistance Level | $3.35 | $4.74 |
| Average True Range (ATR) | 0.14 | 0.43 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 1.26 | 4.62 |
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.